Details of the Drug

General Information of Drug (ID: DMKOTUJ)

Drug Name
SRX246
Indication
Disease Entry ICD 11 Status REF
Huntington disease 8A01.10 Phase 2 [1]
Post-traumatic stress disorder 6B40 Phase 2 [2]
Intermittent explosive disorder 6C73 Phase 1/2 [3]
Anxiety disorder 6B00-6B0Z Phase 1 [4]
Fear-related disorder 6B0Z Phase 1 [4]
Drug Type
Small molecular drug
Cross-matching ID
PubChem CID
44428550
TTD ID
DNS58L
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Antagonist [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Huntington disease
ICD Disease Classification 8A01.10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vasopressin V1a receptor (V1AR) DTT AVPR1A 8.89E-04 -0.12 -0.34
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02507284) Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02733614) Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02055638) Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009). U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT02922166) Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans. U.S. National Institutes of Health.
5 Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16;9(11):3682.